Aims To investigate the annual and monthly hospital incidence rate of rhegmatogenous retinal detachments (RRDs) from 2010 to 2016 in France at the national and regional levels.
Methods In this nationwide database study, we identified hospital and clinic admissions of French residents for a first episode of RRD in France during 2010–2016 from the national administrative database. The annual and monthly hospital incidence rates of RRD per 100 000 population were calculated for the whole country and for each region.
Results The average annual national hospital incidence rate of RRD was 21.97±1.04 per 100 000 population. The annual national hospital incidence rate of RRD was the lowest in 2010 (20.91 per 100 000 population) after which it increased until 2015 (23.55 per 100 000 population). The average monthly national RRD hospital incidence rate was the highest in June (2.03±0.12 per 100 000 population) and the lowest in August (1.60±0.09). The average annual age-standardised and sex-standardised regional hospital incidence rate was the highest in Guadeloupe and Pays de la Loire (28.30±2.74 and 26.13±0.84 per 100 000 population, respectively) and the lowest in French Guiana and Martinique (15.51±3.50 and 17.29±2.12 per 100 000 population, respectively).
Conclusions The average annual national hospital incidence rate of RRD increased from 2010 to 2015. The hospital incidence rate of RRD seemed to vary according to season and geographical location.
- treatment surgery
Statistics from Altmetric.com
Contributors Conception and design: IBG, ASM, EB, P-HG, AMB, CQ, CPC-G. Data acquisition: IBG, ASM, EB, FB, CQ. Drafting the article: IBG, AMB, CPC-G. Final approval of the version to be published: IBG, ASM, EB, P-HG, FB, AMB, CQ, CPC-G.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Map disclaimer The depiction of boundaries on this map does not imply the expression of any opinion whatsoever on the part of BMJ (or any member of its group) concerning the legal status of any country, territory, jurisdiction or area or of its authorities. This map is provided without any warranty of any kind, either express or implied.
Competing interests AMB is a consultant for Aerie, Allergan, Bausch Lomb, Santen and Théa. CPC-G is a consultant for Alcon, Allergan, Bausch Lomb, Bayer, Horus, Novartis, Roche and Théa.
Patient consent for publication Not required.
Ethics approval The use of the PMSI database was approved by the National Commission for Data Protection (Commission Nationale de l’Informatique et des Libertés no. 919086), and this study adhered to the tenets of the Declaration of Helsinki.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement Data may be obtained from a third party and are not publicly available. Pseudoanonymised and encrypted data were extracted from the health data hub. Data were handled by authorised personnel in Dijon University Hospital according to health data hub security guidelines.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.